Allink Biotherapeutics: $47 Million Series A Extension Raised To Advance Two ADC Programs And Expand Multispecific Platforms
By Amit Chowdhry ● Dec 16, 2025
Allink Biotherapeutics, a Shanghai-based clinical-stage biotechnology company developing antibody drug conjugates and multi-specific antibody therapeutics for oncology and immunology, has completed extension rounds of its Series A financing, raising $47 million. The company said the extension rounds were led by existing supporter Legend Capital and new investor Meituan Long Z Investment, with participation from additional returning and new investors including Lanchi Ventures, Yuanbio Venture Capital, 5Y Capital, Lapam Capital, and Runzhang Venture Capital, among others.